DiaCarta is a leading precision diagnostic company specializing in providing comprehensive one-stop-shop for cancer patient management solutions.
Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.
ISO 13485 certified GMP manufacturing facility
Based in California, USA, with global subsidiaries in Europe and Asia
Innovative R&D lab
CAP-accredited CLIA lab
Affordable Excellence with Unmatched Sensitivity and Specificity
Current genomics technology has improved a lot. We can now detect genetic/somatic mutations in tissue samples (biopsy) and even in body fluids (liquid biopsy). Still, it is tough to find rare genetic changes, especially those in early-stage cancer or residual cancer cells (MRD, or Molecular Residual Disease, monitoring).
XNA technology solves this problem by boosting sensitivity and specificity in traditional platforms like Sanger sequencing, qPCR, ddPCR, and NGS, without changing the existing protocol.
High-throughput and sensitive mutation detection and quantification capability without DNA sequencing
Tools like qPCR and ddPCR are often used to quantify gene copy number and gene expression. But, to get accurate results, we first need to extract and purify the DNA or RNA from samples. The problem is, during the extraction, we will lose some DNA or RNA. This becomes a big concern when we only have a small amount of samples to start with.
isobDNA™ technology solves the problem because it does require the sample extraction process. Instead of amplifying the targets like PCR technology, isobDNA technology amplifies the signals. It’s just as sensitive as PCR but more accurate.
DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test, designed for tumor response monitoring, is now eligible for reimbursement from Medicare, effective January 1, 2024.
DiaCarta announced today that DiaCarta received US FDA 510(k) clearance for it’s over the counter (OTC) at home iColon Fecal Occult Blood Test (FOBT) that enables early detection of blood in stool at home, which is clinically relevant in gastrointestinal disorders and colorectal cancer.
As a relatively newly discovered autoinflammatory disease, VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is associated with mutations in the UBA1 gene. Diagnosis of the disease relies on the testing of genetic mutation in patients. What are...
Diagnosis of the VEXAS syndrome improves medical management of the disease and provides more effective treatment of the disease, although there is no cure currently. The diagnosis relies on the VEXAS syndrome genetic testing, a test for a mutation present in the UBA1...